Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
The price of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) closed at $43.01 in the last session, up 0.61% from day before closing price of $42.75. In other words, the price has increased by $0.61 from its previous closing price. On the day, 1.09 million shares were traded. RARE stock price reached its highest trading level at $43.12 during the session, while it also had its lowest trading level at $41.81.
Ratios:
We take a closer look at RARE’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 2.28 and its Current Ratio is at 2.43. In the meantime, Its Debt-to-Equity ratio is 6.65 whereas as Long-Term Debt/Eq ratio is at 6.25.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, RBC Capital Mkts on April 22, 2024, initiated with a Outperform rating and assigned the stock a target price of $77.
On December 08, 2023, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $72.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on May 02 ’24 when Crombez Eric sold 354 shares for $43.66 per share. The transaction valued at 15,456 led to the insider holds 48,431 shares of the business.
Crombez Eric sold 142 shares of RARE for $6,262 on Apr 18 ’24. The EVP and Chief Medical Officer now owns 48,785 shares after completing the transaction at $44.10 per share. On Mar 11 ’24, another insider, Kassberg Thomas Richard, who serves as the CBO & EVP of the company, sold 11,509 shares for $49.93 each. As a result, the insider received 574,644 and left with 252,823 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RARE now has a Market Capitalization of 3575563008 and an Enterprise Value of 4092924672. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.00 while its Price-to-Book (P/B) ratio in mrq is 25.48. Its current Enterprise Value per Revenue stands at 9.248 whereas that against EBITDA is -7.43.
Stock Price History:
Over the past 52 weeks, RARE has reached a high of $54.98, while it has fallen to a 52-week low of $31.52. The 50-Day Moving Average of the stock is -9.08%, while the 200-Day Moving Average is calculated to be 2.16%.
Shares Statistics:
According to the various share statistics, RARE traded on average about 724.32K shares per day over the past 3-months and 792000 shares per day over the past 10 days. A total of 82.31M shares are outstanding, with a floating share count of 77.02M. Insiders hold about 6.45% of the company’s shares, while institutions hold 104.14% stake in the company. Shares short for RARE as of 1713139200 were 4382486 with a Short Ratio of 6.05, compared to 1710460800 on 3780931. Therefore, it implies a Short% of Shares Outstanding of 4382486 and a Short% of Float of 6.15.
